Insider Transactions Reported by 18 Insiders of LB PHARMACEUTICALS INC

Symbol: LBRX on Nasdaq
Location: New York, NY

Quick Takeaways

LBRX - LB PHARMACEUTICALS INC has 18 insiders with reported activity on this page.
Net insider value flow over the last year: +$10,000,004.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $10,000,004; sell value: $0.
Net share flow: <span class="text-green-600">+472,369</span>.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$10,000,004.

Buys

$10,000,004

Shares: 472,369

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$10,000,004

Shares: +472,369

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	472,369	$10,000,004	$0	+$10,000,004
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

LB PHARMACEUTICALS INC executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Deep Track Biotechnology Master Fund, Ltd.	10%+ Owner	$10,000,003	+$10,000,004	+100%	Filing P/S	06 Feb 2026
Marc L. Panoff	Senior Vice President, Finance	$177,187			Mixed	10 Sep 2025
Rekha Hemrajani	Director				Mixed	10 Sep 2025
Heather D. Turner	Chief Executive Officer, Director				Mixed	10 Sep 2025
William P. Kane Jr.	Director				Mixed	10 Sep 2025
Rebecca Luse	Director				Mixed	10 Sep 2025
Robert R. Ruffolo	Director				Mixed	10 Sep 2025
Zachary Prensky	Director				Mixed	10 Sep 2025
J. Scott Garland	Director				Mixed	10 Sep 2025
Vida Ventures GP III, L.L.C.	10%+ Owner				Mixed	12 Sep 2025
Ran Nussbaum	Director				Mixed	12 Sep 2025
Pontifax Management 4 G.P. (2015) Ltd.	10%+ Owner				Mixed	12 Sep 2025
Richard Anthony Silva	SVP, Technical Operations				Mixed	10 Sep 2025
Anna Eramo	Chief Medical Officer				Mixed	10 Sep 2025
Deep Track Special Opportunities Fund, LP	10%+ Owner				Mixed	12 Sep 2025
Panandiker Kaya Kamlesh Pai	Chief Commercial Officer				Mixed	10 Dec 2025
Robert A. Lenz	Director				Mixed	06 Mar 2026
Gad Soffer	Chief Business Officer				Mixed	10 Sep 2025

Top shareholders of LB PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Deep Track Capital, LP	13F 13D/G	Company	15% from 13D/G	3,352,804	$74,633,417	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	5.1% from 13D/G	2,238,934	$49,838,671	—	31 Dec 2025	13F 13D/G
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G	Company	8.7% from 13D/G	2,208,604	$49,163,525	—	31 Dec 2025	13F 13D/G
TCG Crossover Management, LLC	13F	Company	6.9%	1,745,015	$38,844,034	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F 13D/G	Company	6.3% from 13D/G	1,611,482	$35,871,589	—	31 Dec 2025	13F 13D/G
Commodore Capital LP	13F 13D/G	Company	5.5% from 13D/G	1,500,000	$33,390,000	—	31 Dec 2025	13F 13D/G
Trails Edge Capital Partners, LP	13F 13D/G	Company	5% from 13D/G	1,395,608	$31,066,234	—	31 Dec 2025	13F 13D/G
Logos Global Management LP	13F	Company	4.7%	1,200,000	$26,712,000	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	4.4%	1,112,978	$24,774,891	—	31 Dec 2025	13F
Spruce Street Capital LP	13F	Company	4%	1,005,593	$22,384,500	—	31 Dec 2025	13F
BlackRock Portfolio Management LLC	13D/G	—	3.8%	961,158	$21,391,244	-$308,063	31 Dec 2025	13D/G
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	3.5%	896,806	$19,962,902	—	31 Dec 2025	13F
JENNISON ASSOCIATES LLC	13F	Company	3.2%	821,852	$18,294,425	—	31 Dec 2025	13F
Vivo Capital, LLC	13F	Company	3.2%	800,000	$17,808,000	—	31 Dec 2025	13F
Alyeska Investment Group, L.P.	13F	Company	2.7%	675,000	$15,025,500	—	31 Dec 2025	13F
Nantahala Capital Management, LLC	13F	Company	2.7%	675,000	$15,025,500	—	31 Dec 2025	13F
Deep Track Biotechnology Master Fund, Ltd.	3/4/5	10%+ Owner	— mixed-class rows	3,825,173 mixed-class rows	$10,000,003	+$10,000,004	06 Feb 2026	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.7%	441,454	$9,829,858	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	1.6%	407,668	$9,074,690	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.2%	303,115	$6,747,340	—	31 Dec 2025	13F
Nan Fung Group Holdings Ltd	13F	Company	1.2%	300,000	$6,678,000	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.98%	250,030	$5,565,668	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.87%	221,865	$4,938,715	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	0.79%	200,000	$4,452,000	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.76%	193,544	$4,308,289	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.7%	177,616	$3,953,732	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.57%	143,966	$3,204,684	—	31 Dec 2025	13F
HighVista Strategies LLC	13F	Company	0.55%	140,107	$3,118,782	—	31 Dec 2025	13F
Integral Health Asset Management, LLC	13F	Company	0.39%	100,000	$2,226,000	—	31 Dec 2025	13F
Longbow Finance SA	13F	Company	0.32%	82,336	$1,832,799	—	31 Dec 2025	13F
Boxer Capital Management, LLC	13F	Company	0.28%	70,000	$1,558,200	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.2%	50,713	$1,128,872	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.17%	43,758	$974,053	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.16%	40,517	$901,908	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.13%	31,733	$706,377	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.12%	30,215	$672,586	—	31 Dec 2025	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.12%	30,000	$667,800	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.1%	24,641	$548,509	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.09%	22,966	$511,223	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.09%	22,303	$496,465	—	31 Dec 2025	13F
Focus Partners Wealth	13F	Company	0.08%	20,095	$447,315	—	31 Dec 2025	13F
NORGES BANK	13F	Company	0.08%	20,000	$445,200	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.08%	19,121	$425,633	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.07%	18,014	$400,992	—	31 Dec 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.06%	16,283	$362,454	—	31 Dec 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.05%	13,298	$296,014	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.05%	12,720	$283,147	—	31 Dec 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.05%	12,445	$277,026	—	31 Dec 2025	13F
MetLife Investment Management, LLC	13F	Company	0.04%	11,104	$247,175	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.04%	11,074	$247,000	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for LB PHARMACEUTICALS INC

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Robert A. Lenz	LBRX	Stock Option (Right to Buy)	Award				20,000	20,000	06 Mar 2026	Direct
Deep Track Biotechnology Master Fund, Ltd.	LBRX	Pre-Funded Warrants (Right to Buy)	Purchase		$1,988,383	$21.17	93,925	93,925	06 Feb 2026	By Deep Track Special Opportunities Fund, LP
Deep Track Biotechnology Master Fund, Ltd.	LBRX	Pre-Funded Warrants (Right to Buy)	Purchase		$8,011,622	$21.17	378,444	378,444	06 Feb 2026	Direct
Panandiker Kaya Kamlesh Pai		Employee Stock Option (Right to Buy)	Award				195,000	195,000	10 Dec 2025	Direct
Deep Track Biotechnology Master Fund, Ltd.		Common Stock	Purchase				666,666	666,666	12 Sep 2025	By Deep Track Special Opportunities Fund, LP
Deep Track Biotechnology Master Fund, Ltd.		Common Stock	Purchase	291.5%			2,000,000	2,686,138	12 Sep 2025	Direct
Deep Track Biotechnology Master Fund, Ltd.		Common Stock	Conversion of derivative security				686,138	686,138	12 Sep 2025	Direct
Deep Track Biotechnology Master Fund, Ltd.		Series C Preferred Stock	Conversion of derivative security	-100%			-16,666,667	0	12 Sep 2025	Direct
Pontifax Management 4 G.P. (2015) Ltd.		Common Stock	Purchase	242.9%			1,000,000	1,411,681	12 Sep 2025	See footnote
Pontifax Management 4 G.P. (2015) Ltd.		Common Stock	Conversion of derivative security				411,681	411,681	12 Sep 2025	See footnote
Pontifax Management 4 G.P. (2015) Ltd.		Series C Preferred Stock	Conversion of derivative security	-100%			-10,000,000	0	12 Sep 2025	See footnotes
Ran Nussbaum		Common Stock	Purchase	242.9%			1,000,000	1,411,681	12 Sep 2025	See footnote
Ran Nussbaum		Common Stock	Conversion of derivative security				411,681	411,681	12 Sep 2025	See footnote
Ran Nussbaum		Series C Preferred Stock	Conversion of derivative security	-100%			-10,000,000	0	12 Sep 2025	See footnotes
Vida Ventures GP III, L.L.C.		Common Stock	Purchase	60.8%			767	2,029	12 Sep 2025	By Vida Ventures III-A, L.P.
Vida Ventures GP III, L.L.C.		Common Stock	Purchase	60.7%			332,566	880,214	12 Sep 2025	By Vida Ventures III, L.P.
Vida Ventures GP III, L.L.C.		Common Stock	Conversion of derivative security				1,262	1,262	12 Sep 2025	By Vida Ventures III-A, L.P.
Vida Ventures GP III, L.L.C.		Common Stock	Conversion of derivative security				547,648	547,648	12 Sep 2025	By Vida Ventures III, L.P.
Vida Ventures GP III, L.L.C.		Series C Preferred Stock	Conversion of derivative security	-100%			-30,667	0	12 Sep 2025	By Vida Ventures III-A, L.P.
Vida Ventures GP III, L.L.C.		Series C Preferred Stock	Conversion of derivative security	-100%			-13,302,666	0	12 Sep 2025	By Vida Ventures III, L.P.
Marc L. Panoff		Employee Stock Option (Right to Buy)	Award				118,134	90,525	10 Sep 2025	Direct
Marc L. Panoff		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-27,609	0	10 Sep 2025	Direct
Rekha Hemrajani		Stock Option (Right to Buy)	Award				22,449	22,449	10 Sep 2025	Direct
Rebecca Luse		Stock Option (Right to Buy)	Award				22,449	22,449	10 Sep 2025	Direct
William P. Kane Jr.		Stock Option (Right to Buy)	Award				22,449	22,449	10 Sep 2025	Direct
Robert R. Ruffolo		Stock Option (Right to Buy)	Award				35,715	22,449	10 Sep 2025	Direct
Robert R. Ruffolo		Stock Option (Right to Buy)	Disposed to Issuer	-100%			-13,266	0	10 Sep 2025	Direct
Zachary Prensky		Stock Option (Right to Buy)	Award				100,260	53,787	10 Sep 2025	Direct
Zachary Prensky		Stock Option (Right to Buy)	Disposed to Issuer	-100%			-77,811	0	10 Sep 2025	Direct
Ran Nussbaum		Stock Option (Right to Buy)	Award				22,449	22,449	10 Sep 2025	Direct
J. Scott Garland		Employee Stock Option (Right to Buy)	Award				43,963	22,449	10 Sep 2025	Direct
J. Scott Garland		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-21,514	0	10 Sep 2025	Direct
Richard Anthony Silva		Employee Stock Option (Right to Buy)	Award				89,863	80,899	10 Sep 2025	Direct
Richard Anthony Silva		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-8,964	0	10 Sep 2025	Direct
Anna Eramo		Employee Stock Option (Right to Buy)	Award				188,980	155,812	10 Sep 2025	Direct
Anna Eramo		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-33,168	0	10 Sep 2025	Direct
Gad Soffer		Employee Stock Option (Right to Buy)	Award				256,753	229,860	10 Sep 2025	Direct
Gad Soffer		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-26,893	0	10 Sep 2025	Direct
Heather D. Turner		Employee Stock Option (Right to Buy)	Award				1,155,391	971,828	10 Sep 2025	Direct
Heather D. Turner		Employee Stock Option (Right to Buy)	Disposed to Issuer	-100%			-183,563	0	10 Sep 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.